Wolverine Stack
BPC-157 + TB-500 | Tissue Repair & Recovery Protocol
On this page
What is Wolverine Stack?
The Wolverine Stack is a research combination pairing two peptides — BPC-157 and TB-500 — that researchers study together for potentially complementary tissue-repair pathways in animal and preclinical models. A small clinical study looked at the combination in a joint-pain research context, reported here as third-party research findings. Research-grade material sold here is intended for laboratory study only, not for use in people or animals.
Key terms:
Wolverine Stack is a combination protocol (bpc-157 + tb-500).
The Wolverine Stack is not one molecule. It is a blend of two peptides: BPC-157 (Body Protection Compound-157) and TB-500, a fragment of thymosin beta-4. The name comes from the Marvel character known for regenerative abilities. It is marketed around tissue-repair research pathways that researchers describe as complementary. BPC-157 has been studied for increased actin production and for angiogenesis through nitric oxide modulation. TB-500 has been studied for actin-binding effects that help cells migrate and reduce scarring. A 2021 clinical study reported that 87.5% of patients experienced knee pain relief using BPC-157 alone or in combination with TB4.
Key research areas
- Combines two peptides studied for complementary tissue-repair mechanisms: BPC-157 for angiogenesis and inflammation, TB-500 for cell migration and scarring
- A 2021 clinical study reported 87.5% knee-pain improvement in patients using BPC-157 alone or with TB-500
- Tendon and ligament repair research reported in animal models
- Muscle regeneration studied via a dual-pathway mechanism
- Preliminary research on cartilage repair via chondrocyte activity
Researched dosing
This table reflects the dosing schedules researchers have used when studying BPC-157 and TB-500 together, presented as research methodology reference, not personal usage guidance.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| General recovery protocols | BPC-157: 250mcg 2x/day + TB-500: 2mg 2x/week | BPC-157 daily, TB-500 twice weekly | Subcutaneous |
| Higher-dose injury-recovery models | BPC-157: 500mcg 2x/day + TB-500: 2.5mg 2x/week | BPC-157 daily, TB-500 twice weekly | Subcutaneous near injury site |
| Maintenance protocol | BPC-157: 250mcg 1x/day + TB-500: 2mg 1x/week | BPC-157 daily, TB-500 weekly | Subcutaneous |
| Localized joint protocol | Per clinical guidance - based on Lee & Padgett study | As directed by practitioner | Intra-articular (clinical setting only) |
Commonly cycled 8 weeks on, 4+ weeks off.
How it works
At the cell level, research on this combination looks at how BPC-157's effects on blood-vessel formation and TB-500's effects on cell migration might work together — each peptide's individual research is described on its own entry; the term below (angiogenesis) names one of the shared processes studied.
BPC-157 increases actin production at gene level and modulates nitric oxide for vascular effects. TB-500 is an actin-binding protein that sequesters actin for cell migration. Together they enhance fibroblast and immune cell movement to injury sites through synergistic actin regulation.
Research applications
This section summarizes the research areas — tissue repair and wound healing chief among them — that animal studies and a small clinical study have investigated for this two-peptide combination; it's a summary of what's been studied in the literature, not medical claims about people.
Tissue Repair
Both peptides have reported evidence in tendon and ligament repair research: BPC-157 was associated with improved Achilles tendon healing in animal models, and with muscle regeneration in preclinical studies; TB-500 is studied for cell migration relevant to muscle repair. The Lee & Padgett study reported 87.5% of knee-pain patients improved with BPC-157/TB4. Preliminary research suggests possible cartilage-repair effects via chondrocyte activity.
Wound Healing
Wound-healing research through complementary mechanisms: BPC-157 studied for angiogenesis and anti-inflammatory effects, TB-500 studied for cell migration and reduced scarring. Thymosin β4 clinical trials reported wound healing roughly one month faster than comparators in patients with stasis and pressure ulcers.
Anti Inflammatory
Moderate anti-inflammatory effects through BPC-157's nitric oxide modulation and immune cell regulation, combined with TB-500's reduction in scarring response.
Dosage reference
- Doses used in research
- BPC-157 250–500 mcg with TB-500 2–2.5 mg
- Frequency in studies
- BPC-157: 1-2x daily, TB-500: 2x weekly (e.g., Mon/Thu)
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Initial effects: 1-2 weeks. Significant improvement: 4-6 weeks. Full protocol: 8 weeks
- Storage
- Lyophilized: room temp ok. Reconstituted: refrigerate, use within 3-4 weeks
- Cycle length
- 4-8 weeks
- Break between cycles
- 4 weeks off recommended between cycles
Interactions
This list shows which other recovery-research compounds are studied alongside this combination, and why.
Reconstitution & storage
This describes the standard laboratory method for preparing research solutions of each peptide separately before combining doses — a chemistry-handling note for lab use, not a usage guide.
- Reconstitute each peptide separately in its own vial
- For BPC-157: Add 2mL BAC water to 5mg vial = 250mcg per 0.1mL
- For TB-500: Add 2mL BAC water to 5mg vial = 250mcg per 0.1mL
- Inject slowly along vial wall, swirl gently - never shake
- Do NOT mix peptides in same syringe unless from pre-made blend
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: Room temperature acceptable for short-term; 2-8°C preferred, use within Per manufacturer expiration date
Reconstituted: 2-6°C, use within 3-4 weeks
Open the Wolverine Stack reconstitution calculatorQuality indicators
These are the visual and lab-report checks researchers use to confirm both peptide samples in this combination are pure and correctly identified before use in a study.
White Lyophilized Powder - Both BPC-157 and TB-500 vials should contain white or off-white fluffy powder cake. Indicates proper freeze-drying.
Clear After Reconstitution - When mixed with bacteriostatic water, both solutions should be crystal clear with no particles or cloudiness.
Minor Clumping Acceptable - Small clumps that dissolve completely with gentle swirling are normal. Shipping can cause minor compaction of powder.
Collapsed or Discolored - If powder appears collapsed, yellowed, or stuck to vial sides, it may be degraded from heat exposure - do not use.
Cloudy or Particles - Persistent cloudiness or visible particles after reconstitution indicate contamination or degradation - discard vial.
Certificate of Analysis - Reputable suppliers provide HPLC purity testing (>98%) and mass spectrometry verification for both peptides.
What to expect
This timeline summarizes what animal-model and small clinical studies have reported at each stage of research on this combination — research context for comparing studies, not a personal-results promise.
Possible reduction in acute inflammation and pain at injury sites
Noticeable improvement in recovery between workouts, reduced soreness
Significant improvement in chronic injuries, improved joint comfort
Optimal healing effects, structural improvements in damaged tissues
Safety notes
This section covers handling cautions and regulatory notes for this combination — neither peptide is FDA-approved, and this reflects investigational research-use scope, not medical advice.
- Contraindicated with ANY history of cancer or suspicious growths
- Limited human safety data - most research is preclinical
- Do not combine with chemotherapy or in active malignancy
- Monitor for unusual tissue growth or changes
- Not recommended during pregnancy or breastfeeding
- Consult healthcare provider before use, especially with existing conditions
- Not FDA approved - research chemical only
- Banned by WADA and major sports organizations
Regulatory status
- Not approved by the FDA for any indication.
- Prohibited by the World Anti-Doping Agency (WADA).
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
Comprehensive review of BPC-157 in orthopedics. Preclinical models showed improvements in muscle tears, tendon ruptures, ligament tears, and fracture healing. Mechanism involves enhanced GH receptor expression and angiogenesis with reduced inflammatory cytokines. (Vasireddi et al., 2025)
First published study combining BPC-157 and thymosin beta-4 in 16 patients. Overall 87.5% (14/16) experienced knee pain relief. BPC-157 alone: 91.6% improvement. BPC-157 + TB4 combination: 75% improvement. (Lee & Padgett, 2021)
Thymosin β4 accelerated wound healing by approximately one month in patients with stasis and pressure ulcers in two Phase 2 clinical trials. (Treadwell et al., 2012)